Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions
View original at finance.yahoo.comZacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions For Immediate Release Chicago, IL – February 3, 2026 – Today, Zacks Equity Research discusses Boston Scientific BSX, ResMed RMD, Phibro Animal Health PAHC and BioLife Solutions BLFS…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Company faced $100 million tariff headwind in 2025
80% confidenceThe rise of GLP-1 medication is acting as a tailwind for certain medical device sectors, like CPAP therapy
80% confidenceConcomitant procedures expected to grow from 25% to over 50% of WATCHMAN cases
80% confidenceRising adoption of GLP-1 drugs is acting as a significant demand generator for ResMed
80% confidenceZacks top stock-picking strategies have blown away the S&P's +7.7% average gain per year since 2000, with average gains of +48.4%, +50.2% and +56.7% per year
80% confidenceThe ASC market is set to reach $205 billion by 2030
80% confidenceBoston Scientific is focusing on improving margins further by 150 bps over its current long-range plan
80% confidenceBoston Scientific has committed to drive more-than 10% growth over the next three years
80% confidenceTop 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1
80% confidenceResMed has doubled its manufacturing capabilities in the United States, ensuring less than two-day delivery for the majority of its products
80% confidenceThe Zacks Medical Products industry is grappling with a challenging operating environment amid rising tariff concerns
80% confidenceRemote patient monitoring platforms are projected to reach $57 billion by 2030
80% confidenceCompany delivered a 310 bps improvement in gross margin during fiscal first quarter
80% confidenceCompany expects weighted average market growth rate to increase to 9% over the next three years from approximately 8% in 2025
80% confidenceBPM products embedded in 16 approved therapies and 30+ Phase III trials
80% confidenceCurrently there are more than 1350 FDA-cleared AI/ML-enabled devices
80% confidenceData from STANCE trial on AGENT drug-coated balloon will help expand addressable market by three times within percutaneous coronary interventions
80% confidenceSurgical robotics poised for 10.5% CAGR
80% confidenceReal-world data has demonstrated that patients receiving GLP-1 drugs are 10-11% more likely to start CPAP therapy for sleep disorder
80% confidence
Data points we hold from this source
| U.S. Food and Drug Administration · ai devices cleared | 1350 devices |